A deeply trusted “dual-engine” safety-and-medical leader is finally converting resilience into margin expansion—yet still trades at a steep governance-driven discount.
Overview
Drägerwerk is a 135-year German “hidden champion” with entrenched brand trust in life-critical environments, spanning medical technology and industrial safety. After post-pandemic volatility and a China-driven medical downturn in 2024, management has pivoted decisively toward “efficiency before growth,” targeting structural EBIT margin expansion of roughly 1 percentage point per year. The market discounts the shares due to the KGaA governance structure (limited minority influence, no takeover premium) and historically lower margins versus pure-play peers, yet recent results show tangible progress: Q3 2025 delivered ~10% FX-adjusted revenue growth and EBIT more than doubled to €56.7M, aided by gross margin expansion to 45.6%. Valuation appears dislocated (2026E P/E ~9.6x vs peers at ~15x–24x), offering a margin of safety if execution continues. Key risks are the lingering FDA warning letter (limiting US product cadence), fragile China recovery, and geopolitical/tariff and FX headwinds. The recommendation is ACCUMULATE with a 12-month target of €84.